GAM Holding AG Acquires Shares of 120,331 iKang Healthcare Group Inc (KANG)

GAM Holding AG acquired a new stake in shares of iKang Healthcare Group Inc (NASDAQ:KANG) during the second quarter, HoldingsChannel.com reports. The fund acquired 120,331 shares of the medical research company’s stock, valued at approximately $2,462,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Fosun International Ltd raised its stake in shares of iKang Healthcare Group by 0.3% during the first quarter. Fosun International Ltd now owns 4,625,806 shares of the medical research company’s stock valued at $92,284,000 after purchasing an additional 15,372 shares during the period. Maso Capital Partners Ltd raised its stake in shares of iKang Healthcare Group by 15.1% during the first quarter. Maso Capital Partners Ltd now owns 1,731,257 shares of the medical research company’s stock valued at $34,539,000 after purchasing an additional 227,195 shares during the period. Kontiki Capital Management HK Ltd. raised its stake in shares of iKang Healthcare Group by 308.6% during the first quarter. Kontiki Capital Management HK Ltd. now owns 1,364,522 shares of the medical research company’s stock valued at $27,222,000 after purchasing an additional 1,030,609 shares during the period. Athos Capital Ltd raised its stake in shares of iKang Healthcare Group by 159.4% during the first quarter. Athos Capital Ltd now owns 1,247,447 shares of the medical research company’s stock valued at $24,887,000 after purchasing an additional 766,586 shares during the period. Finally, BlackRock Inc. raised its stake in shares of iKang Healthcare Group by 10.3% during the first quarter. BlackRock Inc. now owns 883,929 shares of the medical research company’s stock valued at $17,635,000 after purchasing an additional 82,195 shares during the period. Institutional investors own 52.42% of the company’s stock.

KANG stock opened at $18.90 on Monday. iKang Healthcare Group Inc has a twelve month low of $13.15 and a twelve month high of $21.01. The company has a debt-to-equity ratio of 0.10, a current ratio of 0.67 and a quick ratio of 0.65. The company has a market cap of $1.31 billion, a PE ratio of 72.69 and a beta of 0.07.

iKang Healthcare Group (NASDAQ:KANG) last released its quarterly earnings results on Thursday, June 21st. The medical research company reported ($0.49) earnings per share for the quarter. iKang Healthcare Group had a positive return on equity of 4.67% and a negative net margin of 3.07%. The company had revenue of $89.53 million for the quarter.

A number of analysts have recently issued reports on the stock. BidaskClub upgraded shares of iKang Healthcare Group from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 4th. TheStreet lowered shares of iKang Healthcare Group from a “c” rating to a “d+” rating in a research note on Wednesday, August 15th. Finally, ValuEngine raised shares of iKang Healthcare Group from a “hold” rating to a “buy” rating in a research report on Saturday, June 2nd.

iKang Healthcare Group Company Profile

iKang Healthcare Group, Inc, together with its subsidiaries, provides preventive healthcare solutions in the People's Republic of China. The company operates in two segments, Medical Examinations and Other Medical Services, and Dental Services. It offers a range of medical examinations, including internal, gynecology, ophthalmology, ENT, dental, lab tests, electrocardiogram, ultrasound, and X-ray examination items.

Featured Story: New Google Finance Tool and Screening Stocks

Want to see what other hedge funds are holding KANG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iKang Healthcare Group Inc (NASDAQ:KANG).

Institutional Ownership by Quarter for iKang Healthcare Group (NASDAQ:KANG)

Receive News & Ratings for iKang Healthcare Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iKang Healthcare Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply